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Abstract
Objective: To describe the clinical characteristics and outcomes of patients with coronavirus disease 2019
(COVID-19) who developed pneumatosis intestinalis (PI).
Methods: This case series was conducted in intensive care units at two large tertiary care centers within the
Northwell Health System, located in New York State. Patients were included if they were identified as having
confirmed COVID-19 as well as pneumatosis intestinalis from March 16, 2020 to July 31, 2020. Patient
demographics, clinical characteristics, vasopressor use, anticoagulation use, opiate use, paralytic use,
COVID-19 treatment regimen, serum lactate, arterial pH, serum bicarbonate, subsequent intervention, and
outcomes during hospitalization were collected.
Results: A total of nine patients were identified. Average serum lactate was 4.33 mmol/L at time of diagnosis.
Portal venous gas (56%) and bowel dilation (56%) were common radiographic findings. Subsequent morbidity
(increased vasopressor requirements - 67%, acute kidney injury - 67%, increased oxygen requirements 44%) and mortality (78%) were high. PI occurred despite a majority of patients being on anticoagulation
(78%). Interleukin-6 (IL-6) inhibitors were commonly administered (56%) prior to development of PI.
Conclusion: Pneumatosis intestinalis in COVID-19 is clinically significant, with high morbidity and
mortality, and is also likely underdiagnosed.

Categories: Gastroenterology, General Surgery, Infectious Disease
Keywords: covid-19, severe acute respiratory syndrome coronavirus 2, pneumatosis cystoides intestinalis, intestinal
perforation, interleukin-6

Introduction
As of September 15, 2020, the number of confirmed coronavirus disease 2019 (COVID-19) cases have
exceeded 29 million worldwide, resulting in almost one million deaths. As scientific and medical
communities continue efforts to elucidate how the responsible pathogen, severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), can affect the human body, we have discovered many, often unexpected, ways
it can cause harm.
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Pneumatosis intestinalis (PI) refers to the presence of gas within the intestinal wall. Many aspects of this
condition are poorly understood, including etiology, pathogenesis, and clinical implication. Reported
etiologies have been widely varied, including gastroenteritis [1], chronic obstructive pulmonary disease,
bowel obstruction, idiopathic [2], etc. While it may be a benign, incidental finding, it may also herald a lifethreatening condition such as intestinal ischemia. Previous studies have shown that elevated lactate,
vasopressor use, small bowel dilation, peritonitis, and abdominal pain are predictive factors for clinically
significant PI [3-5].
PI has been previously reported in COVID-19 patients, but it has been limited to three single case reports
and a review of abdominal imaging findings in COVID-19 patients. In their review of 134 patients, Bhayana
et al. reported that abdominal computed tomography (CT) detected pneumatosis or portal venous gas in four
of 20 critically ill patients (20%) [6]. In some of these patients, surgical findings showed unusual yellow
discoloration of bowel and bowel infarction while pathology demonstrated ischemic enteritis, patchy
necrosis, and fibrin arteriolar thrombi.
Here, we report a case series of PI in patients with COVID-19 infection and describe their clinical
characteristics and outcomes.

Materials And Methods
Data was collected retrospectively from the electronic medical record (EMR), Enterprise Sunrise Clinical
Manager-Allscripts, for patients with confirmed COVID-19 and pneumatosis intestinalis admitted to North
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Shore University Hospital and Long Island Jewish Medical Center, two large tertiary care centers within the
Northwell Health System, from March 16, 2020 to July 15, 2020. This case series was approved by the
Northwell Institutional Review Board (IRB), as minimal-risk research using data collected for routine clinical
practice and waived the requirement for informed consent (IRB number 20-0200).
A confirmed case of COVID-19 was defined as a positive laboratory test for SARS-CoV-2 from real-time
reverse transcription polymerase chain reaction (RT-PCR) assay of a respiratory specimen. Pneumatosis
intestinalis was identified by abdominal CT. We collected data on patient demographics, comorbidities, time
from symptom onset to PI diagnosis, CT imaging findings, concomitant lab values (serum lactate, arterial
pH, serum bicarbonate), subsequent intervention, COVID-19 treatment regimen, vasopressor use,
anticoagulation use, opiate use, paralytic use, and patient outcomes (change in vasopressor requirements,
change in oxygen requirements, development of acute kidney injury, resolution of PI and in-hospital
mortality).

Results
A total of nine patients were included in our case series. The patients were predominantly male (seven
patients, 77.8%) with an average age of 54.3 years. Three patients were Hispanic (33.3%) with the rest equally
distributed among White, Black, and Asian ethnicities (two patients, 22.2%). The most common comorbidity
was obesity (six patients, 66.7%), followed by hypertension (three patients, 33.3%), diabetes (two patients,
22.2%), and prior history of cerebrovascular accident or transient ischemic attack (two patients, 22.2%). The
average time of symptom onset to PI diagnosis was 22.2 days and the average time of admission to PI
diagnosis was 13.7 days (Table 1).
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Demographics

Total Cohort (n = 9)

Age (years)
Mean [Range]

54.3 [36 – 65]

Gender
Male

7 (78)

Female

2 (22)

BMI (kg/m2)
Mean [Range]

32.8 [23.1 - 56.4]

Normal (18.5 to < 25)

2 (22)

Overweight (25 to < 30)

2(22)

Obese (>30)

5 (56)

Race
Hispanic

3 (33)

White

2 (22)

Asian

2 (22)

Black

2 (22)

Comorbidities
HTN

3 (33)

DM

2 (22)

Prior CVA

2 (22)

CKD

1 (11)

Asthma

1 (11)

Medications at time of diagnosis
Anti-coagulation

7 (78)

Opiate

7 (78)

Vasopressor

5 (56)

Paralytic

3 (33)

COVID-19 Specific Medications
Steroids

6 (67)

Anti-Il 6

5 (55)

Plasma

3 (33)

Plaquenil

3 (33)

Anti-Il 1

2 (22)

Azithromycin

2 (22)

TABLE 1: Patient Demographics and Characteristics
Note: Values are expressed as number (percentage) unless otherwise indicated

Indications for abdominal CT were variable. The majority of scans were performed as part of an infectious
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workup (four patients, 44.4%). Other indications included workup for elevated serum lactate (two patients,
22.2%), abdominal distension (two patients, 22.2%), and confirmation of incidental findings on chest CT
(one patient, 11.1%).
Most patients had pneumatosis of both small and large bowel (six patients, 66.7%), while two patients
(22.2%) had only small bowel involvement and one patient (11.1%) had only large bowel involvement. Portal
venous gas was present in five patients (55.5%). Bowel dilation was also present in five patients (55.5%), of
which three patients (33.3%) had dilated loops of both large and small bowel, while two patients (22.2%) had
dilated loops of small bowel alone (Table 2).
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Clinical Data

Total Cohort (n = 9)

Days from symptom onset to diagnosis of pneumatosis
Mean [Range]

22.2 [4 – 47]

Days from admission to diagnosis of pneumatosis
Mean [Range]

13.7 [0 – 31]

Laboratory Findings
Lactate (mmol/L)
Mean (SD)

4.33 (3.64)

Arterial pH
Mean (SD)

7.22 (0.13)

Bicarbonate (mmol/L)
Mean (SD)

19.33 (5.83)

Radiology Findings (n,%)
Portal Venous Gas

5 (56)

Dilated Bowel Loops

5 (56)

Small Bowel Only

2 (22)

Large Bowel Only

0 (0)

Both

3 (33)

Interventions (n,%)
NPO

9 (100)

Antibiotics

7 (78)

Stopped Bowel Regimens

3 (33)

Total Parenteral Nutrition

2 (22)

Surgical intervention

1 (11)

Outcome (n,%)
Increased Vasopressor Requirements

6 (67)

Acute Kidney Injury

6 (67)

Inpatient Deaths

7 (78)

Discharged

2 (22)

Days from pneumatosis diagnosis to death
Mean [Range]

6.43 [0 – 16]

TABLE 2: Clinical Data

At the time of CT diagnosis of PI, the average serum lactate was 4.33 mmol/L (range 0.8 to 12.4). Average
arterial pH was collected for eight patients, with an average value of 7.22 (range 7.06 to 7.39). Average serum
bicarbonate was 19.33 mmol/L (range 9 to 30) (Table 2).
The majority of patients were on full anticoagulation (seven patients, 77.8%) with four patients on
argatroban and three patients on unfractionated heparin. Most were also on continuous opiate infusions for
sedation (seven patients, 77.8%). Of the patients in our series, five (55.6%) were on vasopressor medications.
A minority of patients were on paralytics (three patients, 33.3%) (Table 1).
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COVID-19-specific therapy included a variety of different regimens. The most commonly used medications
were steroids (six patients, 66.7%) followed by IL-6 inhibitors (five patients, 55.6%), convalescent plasma
(three patients, 33.3%), hydroxychloroquine (three patients, 33.3%), interleukin-1 inhibitors (two patients,
22.2%) and azithromycin (two patients, 22.2%). Two patients (22.2%) received no COVID-19-specific
therapy (Table 1).
After diagnosis of PI, one patient (11.1%) underwent an exploratory laparotomy, which was done emergently
at bedside and revealed necrotic bowel. All other patients were managed conservatively with bowel rest
(100%), empiric antibiotics to cover intestinal flora (77.8%), and discontinuation of bowel regimens (33.3%).
Two patients (22.2%) were also started on total parenteral nutrition (TPN) (Table 2).
Following diagnosis of PI, six patients (66.7%) developed increased vasopressor requirements, six patients
(66.7%) developed acute kidney injury, and four patients (44.4%) developed increased oxygen requirements.
Resolution was demonstrated on interval imaging in two patients (22.2%). In terms of mortality, seven
patients expired (77.8%) and two were discharged (22.2%). For those who expired, the average time from PI
diagnosis to death was 6.4 days (Table 2).

Discussion
To our knowledge, this study is the largest reported case series of pneumatosis intestinalis in COVID-19
patients. In our series, 77.8% of patients who were diagnosed with PI died. A majority of these patients also
developed significant morbidity after the diagnosis of PI, such as increased vasopressor requirements
(66.7%) and acute kidney injury (66.7%). For those who died, average time to death after PI diagnosis was 6.4
days while their average length of stay was 20.4 days (Table 2). These findings suggest that the development
of PI is a poor prognostic factor in COVID-19.
Based on pre-COVID-19 studies on predictive factors for pathologic PI, our results support that the
diagnosis of PI in COVID-19 patients is of clinical significance. Multiple studies have shown that serum
lactate is the most consistent predictor of clinically significant PI. One study showed that lactate levels
greater that 2.0 mmol/L at time of diagnosis has been associated with over 80% mortality [4]. In our case
series, this was true in 77.8% of patients (odds ratio = 21.7). The presence of small bowel dilation has also
been shown to be a predictor, which was present in 55.6% of our patients (odds ratio = 1.3).
The pathophysiology of this process is unclear as many aspects of COVID-19 remain unknown. Recent
COVID-19 autopsy studies have shown a 40% prevalence of deep venous thrombosis, presence of
microthrombi in multiple organ systems, as well evidence of intestinal endothelitis suggesting both macro
and microvascular clotting predisposition [7-9]. However, the majority of patients in our case series
developed PI despite therapeutic anticoagulation (77.8%), suggesting that there may be other contributing
factors. The usage of opiate medications (77.8%) and paralytics (33.3%) with subsequent decreased gut
motility can in theory increase intraluminal pressures and cause intestinal distention, increasing risk for
wall injury.
While each patient had indications for emergent surgical exploration based on pre-COVID-19 studies, risks
of surgical intervention were deemed to outweigh benefits for most. The only patient with surgical
intervention had undergone exploratory laparotomy the same day of PI diagnosis and died the next day. Two
patients (22.2%) had resolution of PI without surgical intervention, one of which survived to discharge. It is
unclear if early surgical intervention would be beneficial.
This manifestation of disease has significant implications on possible treatment modalities of interest.
Recently, “cytokine storm” has been purported to be partly responsible for the high morbidity and mortality
seen in COVID-19. Interleukin-6 inhibitors are being investigated for their potential in stemming
hyperinflammation and its deleterious effects. Tocilizumab, an Il-6 inhibitor, has a known elevated risk of
intestinal perforation [10,11]. Intestinal perforation has also been reported with sarilumab, another
inhibitor. In our group, five patients (55.6%) had received an IL-6 inhibitor with an average time from
administration to PI diagnosis of 11.4 days. Of these five patients, four received tocilizumab and one
received sarilumab. The effect of receiving these medications on their development of PI is unclear.

Conclusions
We describe a case series of COVID-19 patients who developed pneumatosis intestinalis. We believe it is a
clinically significant manifestation of disease that is likely underdiagnosed. Clinical suspicion should be
high in COVID-19 patients with clinical decompensation, rising serum lactate, or worsening abdominal
exam. Further surgical and pathology data is necessary to determine exact pathophysiology.

Additional Information
Disclosures
Human subjects: Consent was obtained by all participants in this study. Northwell Institutional Review
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Board issued approval IRB number 20-0200. Animal subjects: All authors have confirmed that this study did
not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform
disclosure form, all authors declare the following: Payment/services info: All authors have declared that no
financial support was received from any organization for the submitted work. Financial relationships: All
authors have declared that they have no financial relationships at present or within the previous three years
with any organizations that might have an interest in the submitted work. Other relationships: All authors
have declared that there are no other relationships or activities that could appear to have influenced the
submitted work.
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